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II  24, III  38; mean left ventricular ejection fraction 
34.3%  15.5). Mean disease-specific QOL (KCCQ
Overall Summary Score  66.9) and generic QOL (Phys-
ical Component Summary  38.7; Mental Component
Summary  48.2) were similar to literature values for HF
patients. Mean utility was 0.832. Using linear regression,
lower KCCQ scores, SF-12 scores, and utility at baseline
were all significantly associated with higher resource uti-
lization at 3 months. When patients were grouped into
three categories based on their baseline KCCQ Overall
Summary Score (I  0–50, II  50 to £75, III  75),
resource utilization over 3 months was significantly dif-
ferent across the groups (I  $4033; II  $2500; III 
$2010; p  0.0003). CONCLUSION: Among patients
with HF, QOL and patient preference appear to predict
future resource utilization.
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FRAMINGHAM RISK EQUATIONS PREDICT 
HOSPITAL USAGE AND MORTALITY
Milne RJ, Gamble GD, Whitlock G, Jackson RT
University of Auckland, Auckland, New Zealand
Risk equations based on the Framingham Heart Study
(FHS) are used in NZ to predict the 5y risk of incident
cardiovascular (CV) events. OBJECTIVE: To establish
how well the FHS equations predict first hospitalisation
or mortality from CV events in a New Zealand (NZ)
population without overt CV disease. METHODS: Ob-
servations were taken from a cohort study with 6354
(4638 M 1716 F) participants age 32–74 without
known CV disease, taken from the workforce of a na-
tion-wide multi-industry corporation plus a random sam-
ple of the Auckland electoral rolls. Prognostic factors
were assessed in 1992/93 by a questionnaire plus physio-
logical measurements (BP, cholesterol etc.). Age-specific
risk predictions from the FHS were compared with age-
specific mortality plus relevant hospital discharges from
January 1988 to December 1998 (NZ Health Informa-
tion Service). RESULTS: The 5y incidence of first hospi-
talisation for any CV event was 6.4% (male) and 4.4%
(female). Table 1 compares observed hospitalised events
or mortality with predicted incident events, averaged
across 5y age bands.
CONCLUSIONS: FHS risk equations accurately predict
age-specific incident hospitalized CHD or stroke events
or mortality for NZ males age 30–74 but under-estimate
MI events. Prediction is less accurate and precise for fe-
males.
Ratio of observed to predicted events, averaged across 8 	 
5y age bands
Mean ratio (SD) Male Female Both
CHD 1.03  0.15 0.92  0.35 1.03  0.06
MI 1.24  0.19 1.49  1.19 1.26  0.15
STROKE 0.98  0.40 0.74  0.57 0.94  0.42
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DISCRIMINABILITY FOR RISK OF 
CARDIOVASCULAR EVENTS
Milne RJ, Gamble GD, Whitlock G, Irwin RJ, Jackson RT
University of Auckland, Auckland, New Zealand
Risk equations based on the Framingham Heart Study
(FHS) are used in NZ to predict the 5y risk of an incident
CV event for individuals without cardiovascular (CV)
disease. OBJECTIVES: To establish in a NZ population
without overt CV disease: (i) the discriminability of the
relevant FHS risk equation for prediction of first hospi-
talisation or mortality for any cardiovascular event; (ii)
whether FHS risk equations have better discriminability
than single risk factors. METHODS: Observations were
taken from a cohort study with 6354 (4638 M  1716 F)
participants age 32–74 without known CV disease, taken
from the workforce of a nation-wide multi-industry cor-
poration plus a random sample of the Auckland electoral
rolls. Prognostic factors were assessed in 1992–93 by a
questionnaire plus physiological measurements (BP, cho-
lesterol etc.). Outcomes data were CV mortality and hos-
pital discharges from Jan. 1988 to Dec. 1998 (NZ Health
Information Service). Risk predictions were compared
with outcomes, and receiver-operator characteristics
(ROC) curves were constructed. The area under the ROC
curve was obtained by fitting a dual-Gaussian unequal
variance model. RESULTS: Table 1 shows the area under
the ROC curves.
CONCLUSIONS: FHS risk equations or age alone pro-
vide moderate discriminability for individuals with 5y
risk of a CV event that requires hospitalisation. SBP and
serum lipids have weaker discriminability.
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ASSESSING THE TOTAL COST OF 
MANAGEMENT OF A PATIENT WITH DEEP VEIN 
THROMBOSIS (DVT) IN FRANCE AND IN ITALY
Levy E1, Gabriel S2, Dinet J2, Rudelli G3
1University Paris-Dauphine, Paris, France; 2Sanofi-Synthelabo, 
Bagneux, France; 3Sanofi-Synthelabo SPA, Milano, Italy
OBJECTIVES: Economic studies on the cost of DVT usu-
ally take into account the acute care costs only although
the patients are treated and followed-up after hospital
discharge for at least six months. We calculated the true
economic burden of the disease. METHODS: We as-
sessed from the Health Care System perspective the total
cost of managing a patient with DVT over a one-year
Area under ROC curves (95% CI).
Male Female Total
FHS .72  .030 .78  .055 .74  .025
Age .70  .029 .77  .058 .71  .026
SBP .62  .034 .69  .062 .64  .030
Chol/HDLc .61  .034 .64  .066 .63  .030
BMI .56  .034 .61  .063 .58  .029
